[{"id":"877e6060-0685-49ad-bf87-696fb090b715","acronym":"","url":"https://clinicaltrials.gov/study/NCT03218826","created_at":"2021-01-18T15:52:53.855Z","updated_at":"2025-02-25T16:51:57.310Z","phase":"Phase 1","brief_title":"PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03218826","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PTEN • PIK3CB","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • AZD8186"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 07/25/2022","primary_completion_date":" 07/25/2022","study_txt":" Completion: 10/03/2025","study_completion_date":" 10/03/2025","last_update_posted":"2025-02-04"},{"id":"19899ca6-56d4-4952-beaa-c4745d820e14","acronym":"","url":"https://clinicaltrials.gov/study/NCT03131908","created_at":"2021-01-18T15:25:52.146Z","updated_at":"2025-02-25T13:12:18.989Z","phase":"Phase 1/2","brief_title":"Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss","source_id_and_acronym":"NCT03131908","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-13"},{"id":"658df07a-1501-4c8c-8a3c-b8a40f1a83dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439149","created_at":"2021-01-18T21:22:06.430Z","updated_at":"2024-07-02T16:35:04.598Z","phase":"Phase 2","brief_title":"Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)","source_id_and_acronym":"NCT04439149","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-09"},{"id":"97b43e3f-fef1-4710-bf54-e72318c22ed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439188","created_at":"2021-01-18T21:22:07.541Z","updated_at":"2024-07-02T16:35:05.160Z","phase":"Phase 2","brief_title":"Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)","source_id_and_acronym":"NCT04439188","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-08"},{"id":"bed0d4a8-8053-4726-881a-8fd3a77fe815","acronym":"","url":"https://clinicaltrials.gov/study/NCT02951091","created_at":"2021-01-18T14:29:37.726Z","updated_at":"2024-07-02T16:36:07.027Z","phase":"Phase 2","brief_title":"Biomarker-Integrated Umbrella, Advanced Gastric Cancer","source_id_and_acronym":"NCT02951091","lead_sponsor":"Yonsei University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-07-20"},{"id":"276d0a32-62b9-4cd9-b652-5c83c87e2a19","acronym":"","url":"https://clinicaltrials.gov/study/NCT02615730","created_at":"2021-01-18T12:42:23.664Z","updated_at":"2024-07-02T16:36:31.358Z","phase":"Phase 1/2","brief_title":"PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma","source_id_and_acronym":"NCT02615730","lead_sponsor":"Yonsei University","biomarkers":" PTEN • PIK3CB","pipe":"","alterations":" ","tags":["PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • GSK2636771"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 03/31/2021","study_completion_date":" 03/31/2021","last_update_posted":"2021-04-22"},{"id":"cd2d3973-b09a-47d1-9905-179fbe08c625","acronym":"","url":"https://clinicaltrials.gov/study/NCT02215096","created_at":"2021-01-18T10:23:00.105Z","updated_at":"2024-07-02T16:36:39.797Z","phase":"Phase 1","brief_title":"Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT02215096","lead_sponsor":"GlaxoSmithKline","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • GSK2636771"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 11/13/2014","start_date":" 11/13/2014","primary_txt":" Primary completion: 10/03/2019","primary_completion_date":" 10/03/2019","study_txt":" Completion: 10/03/2019","study_completion_date":" 10/03/2019","last_update_posted":"2020-10-22"},{"id":"39901d4d-3dee-40b7-99f7-2afa8c1da147","acronym":"","url":"https://clinicaltrials.gov/study/NCT01884285","created_at":"2021-01-18T08:27:26.840Z","updated_at":"2024-07-02T16:36:44.639Z","phase":"Phase 1","brief_title":"AZD8186 First Time In Patient Ascending Dose Study","source_id_and_acronym":"NCT01884285","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PGR • PTEN • PIK3CB","pipe":" | ","alterations":" HER-2 negative • PIK3CB mutation","tags":["HER-2 • ER • PGR • PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • AZD8186 • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 147","initiation":"Initiation: 07/09/2013","start_date":" 07/09/2013","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 02/07/2020","study_completion_date":" 02/07/2020","last_update_posted":"2020-05-29"},{"id":"653c069b-b3fd-4296-9ec6-b61db80cd0e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04001569","created_at":"2021-01-18T19:40:05.431Z","updated_at":"2024-07-02T16:36:58.529Z","phase":"Phase 1/2","brief_title":"AZD8186 and Paclitaxel in Advanced Gastric Cancer","source_id_and_acronym":"NCT04001569","lead_sponsor":"Seoul National University Bundang Hospital","biomarkers":" PTEN • PIK3CB","pipe":" | ","alterations":" PTEN deletion","tags":["PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AZD8186"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2019-06-28"},{"id":"cc35a732-a32f-424d-b664-a540e6b1f7ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT01458067","created_at":"2021-01-18T06:03:31.538Z","updated_at":"2024-07-02T16:37:08.736Z","phase":"Phase 1/2","brief_title":"A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency","source_id_and_acronym":"NCT01458067","lead_sponsor":"GlaxoSmithKline","biomarkers":" HER-2 • PGR • PTEN","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2636771"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 11/10/2011","start_date":" 11/10/2011","primary_txt":" Primary completion: 11/12/2015","primary_completion_date":" 11/12/2015","study_txt":" Completion: 02/25/2016","study_completion_date":" 02/25/2016","last_update_posted":"2018-07-24"}]